Sunitinib
規格
557795-19-4CAS番号
111-194-2EC番号
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamideIUPAC名
C22H27FN4O2化学式
398.5 g/mol分子量
Sunitinib; 557795-19-4; SU-11248; SU11248; sunitinibum; Su-011248; NSC-750690; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide; SU011248; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; NSC-736511; V99T50803M; n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide; DTXSID1041134; CHEBI:38940; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; N-(2-(diethylamino)ethyl)-5-(((3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; RefChem:56080; DTXCID9021134; L01XE04; 111-194-2; 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide; Sutent; Sunitinib Base; 342641-94-5; N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; MFCD09260778; Sunitinib (INN); Sunitinib [INN]; C22H27FN4O2; CHEMBL535; SU 11248; NSC750690; Sunitinib (free base); Sunitinib [INN:BAN]; NCGC00164631-01; Sunitinib base?; s7781; UNII-V99T50803M; HSDB 7932; (Z)-Sunitinib; 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; Sutent (free base); Sunitinib (Standard); KS-5022; SUNITINIB [MI]; SUNITINIB [VANDF]; SCHEMBL8081; SUNITINIB [WHO-DD]; SUNITINIB [EMA EPAR]; BDBM4814; GTPL5713; orb1224671; orb1310675; orb3141251; Sutent, Sunitinib, SU11248; CHEBI:91430; EX-A553; WINHZLLDWRZWRT-ATVHPVEESA-N; HMS5085H20; HMS6018M17; HY-10255AR; K00588a; (E)-N-[2-(Diethylamono)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; Sunitinib base - Bio-X trade mark; EBC-12065; HY-10255A; NSC800937; T0374L; AKOS015908193; AKOS025312424; CCG-268638; CS-1670; DB01268; FD32120; NSC 736511; NSC 750690; NSC-800937; SDCCGSBI-0634415.P005; NCGC00164631-02; NCGC00164631-04; NCGC00164631-13; NCGC00164631-21; BD164426; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; SY013948; NS00004661; D08552; EN300-323230; H38037; AB01273976-01; AB01273976-02; AB01273976_04; Q417542; SR-00000000005; SR-00000000005-2; BRD-K42828737-001-03-3; BRD-K42828737-044-09-0; BRD-K42828737-044-10-8; BRD-K42828737-044-12-4; Q27163278; Z2568722545; 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; (Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3-indolinylidene)methyl]-2,4-dimethylpyrrole-3-carboxamide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-ethyl)-amide; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1 pound not2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2 pound not4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carbo別名
Sunitinibを含む製品
SUNITINIB VIATRIS 50 MG CAPSULAS DURAS EFGSUNITINIB VIATRIS 25 MG CAPSULAS DURAS EFGSUNITINIB VIATRIS 12,5 MG CAPSULAS DURAS EFGSUNITINIB TEVA 50 MG CAPSULAS DURAS EFGSUNITINIB TEVA 25 MG CAPSULAS DURAS EFGSUNITINIB TEVA 12,5 MG CAPSULAS DURAS EFGSUNITINIB ACCORD 50 mg CAPSULAS DURAS EFGSUNITINIB ACCORD 37,5 mg CAPSULAS DURAS EFGSUNITINIB ACCORD 25 mg CAPSULAS DURAS EFGSUNITINIB ACCORD 12,5 mg CAPSULAS DURAS EFGSUTENT 50 MG CAPSULAS DURASSUTENT 25 MG CAPSULAS DURAS
1/5ページ
Sunitinibを販売する企業
VS
VIATRIS SANTEFranceSA
SANDOZFranceAH
Accord Healthcare S.L.U.SpainVL
Viatris LimitedSpainPE
PFIZER EUROPE MA EEIGBelgium1/2ページ